Microbiome Modulation for the Treatment of Solid Neoplasms

Area of Science:

• Oncology
• Immunology
• Microbiome Research

Background:

• The gut microbiome's interaction with the immune system is crucial for cancer treatment efficacy.
• Specific gut bacteria are associated with improved responses to immune checkpoint inhibitors (ICIs).
• Antibiotic disruption of the microbiome correlates with resistance and poorer survival in ICI therapy.

Purpose of the Study:

• To explore the role of microbiome modulation as a therapeutic strategy in oncology.
• To review current clinical investigations and potential microbiome-based interventions for cancer patients.
• To assess the impact of gut bacteria, diet, probiotics, and fecal microbiota transplantation on ICI outcomes.

Main Methods:

• Analysis of preclinical and clinical studies investigating the gut microbiome in relation to ICI therapy.
• Correlation of specific bacterial abundances (e.g., Ruminococcaceae, Akkermansia, Bifidobacterium) with clinical outcomes.
• Evaluation of microbiome-modulating strategies including dietary fiber, probiotics, and fecal microbiota transplantation.

Main Results:

• Favorable clinical outcomes in melanoma, renal cell carcinoma (RCC), and non-small cell lung cancer (NSCLC) correlate with specific gut bacteria.
• High dietary fiber intake and certain probiotics show potential in enhancing ICI efficacy.
• Fecal microbiota transplantation demonstrates safety and efficacy in ICI-refractory and treatment-naïve patients.

Conclusions:

• Microbiome modulation presents a promising avenue for improving cancer immunotherapy.
• Further large-scale, randomized trials are essential to establish microbiome-based strategies as standard oncological care.
• Biomarkers like TOPOSCORE can aid in predicting treatment response and dysbiosis.